Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab initiates Phase I/II colorectal cancer study
The study will include a maximum of 97 patients who have failed standard chemotherapy and progressed during or within three months of stopping cetuximab-based therapy. This open label
The study will include a maximum of 97 patients who have failed standard chemotherapy and progressed during or within three months of stopping cetuximab-based therapy. This open label
Bill Worthen, president and CEO of Alsius, said: This is the fifth contract we have been awarded by a major hospital group purchasing organization in the US. We
Under the terms of the agreement, which includes two one-year extension options, Impulse Monitoring (IMI) will provide University of Virginia Health System (UVAHS) with comprehensive intraoperative neuromonitoring (IONM)
The Previstage guanylyl cyclase C (GCC) test employs qRT-PCR technology, which has been shown to be up to 100,000-times more sensitive than traditional histopathology in detecting occult metastases.
The tests measure the over-expression of the enzyme fatty acid synthase (FAS), which is found in virtually all solid tumor cancers. FASgen’s FAS-detect Elisa and FAS-detect IHC tests,
Investors in the first closing of the private placement purchased 1,987,936 shares of the company’s common stock at a price of $1.25 per share and received a five-year
The patent includes claims for optical biosensors and their use in a wide variety of assay formats, including the detection of substances in unpurified biological samples. The patent
Under the terms of the agreement, InSite grants exclusive rights to Essex to commercialize AzaSite for ocular bacterial infection throughout the People’s Republic of China. Essex will also
Under the agreement, Octapharma will use Haemonetics’s technology to separate plasma from donor blood at its US plasma collection centers. Plasma is the source of numerous proteins used
Mr Land, who recently served as CFO of Safeguard Scientifics, replaces James Agnello, who resigned the CFO position earlier this month. Mr Land has more than 30 years